Therapeutic apheresis: history, clinical application, and lingering uncertainties
2009; Wiley; Volume: 50; Issue: 7 Linguagem: Inglês
10.1111/j.1537-2995.2009.02505.x
ISSN1537-2995
Autores Tópico(s)Hemoglobinopathies and Related Disorders
ResumoTransfusionVolume 50, Issue 7 p. 1413-1426 Therapeutic apheresis: history, clinical application, and lingering uncertainties Bruce C. McLeod, Bruce C. McLeod From the Rush University Medical Center Blood Center, Chicago, Illinois.Search for more papers by this author Bruce C. McLeod, Bruce C. McLeod From the Rush University Medical Center Blood Center, Chicago, Illinois.Search for more papers by this author First published: 01 July 2010 https://doi.org/10.1111/j.1537-2995.2009.02505.xCitations: 34 Bruce C. McLeod, MD, Professor of Medicine and Pathology, Rush Medical College, Director, Blood Center, Rush University Medical Center, 1753 West Congress Parkway, Chicago, IL 60612; e-mail: [email protected]. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Surgenor DM. Blood: the red fluid of the human body is a rich mixture of cells and molecules. New methods of fractionation and preserving these many constituents increase their usefulness to medicine. Sci Am 1954; 190: 54-62. 10.1038/scientificamerican0254-54 Google Scholar 2 Tullis JL. Principles involved in glycerolization and deglycerolization of red cells using the Cohn fractionator. In: Proceedings of a Conference on Plasma Proteins and Cellular Elements of the Blood, November 15, 1954. Cambridge (MA): Protein Foundation, Inc. and the Commission on Plasma Fractionation and Related Processes; 1954. p. 17-8. Google Scholar 3 Tullis JL, Tinch RJ, Baudanza P, Gibson JG 2nd, DiForte S, Conneely G, Murthy K. Plateletpheresis in a disposable system. Transfusion 1971; 11: 368-77. 10.1111/j.1537-2995.1971.tb04431.x CASPubMedWeb of Science®Google Scholar 4 Judson G, Jones A, Kellogg R, Buckner D, Eisel R, Perry S, Greenough W. Closed continuous-flow centrifuge. Nature 1968; 217: 816-8. 10.1038/217816a0 CASPubMedWeb of Science®Google Scholar 5 Corbin F, Cullis HM, Freiriech EJ, Ito Y, Kellog RM, Latham A, McLeod BC. Development of apheresis instrumentation. In: BC McLeod, TH Price, R Weinstein, editors. Apheresis: principles and practice. 2nd ed. Bethesda (MD): AABB Press; 2003. p. 1-27. Google Scholar 6 Ito Y, Suaudeau J, Bowman RL. New flow-through centrifuge without rotating seals applied to plasmapheresis. Science 1975; 189: 999-1000. 10.1126/science.1220011 CASPubMedWeb of Science®Google Scholar 7 Colton CK, Henderson LW, Ford CA, Lysaght MJ. Kinetics of hemodiafiltration, I: in vitro transport characteristics of a hollow fiber blood ultrafilter. J Lab Clin Med 1975; 85: 355-71. CASPubMedWeb of Science®Google Scholar 8 Smith JW, Malchesky PS, Nosé Y. Membrane plasmapheresis and the developing technology of plasma therapy. Cleve Clin Q 1984; 51: 135-42. 10.3949/ccjm.51.1.135 CASPubMedWeb of Science®Google Scholar 9 McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion 1999; 39: 282-8. 10.1046/j.1537-2995.1999.39399219285.x CASPubMedWeb of Science®Google Scholar 10 McMinn JR Jr, Thomas IA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. A study of 78 additional patients. Transfusion 2003; 43: 415-6. 10.1046/j.1537-2995.2003.00336.x PubMedWeb of Science®Google Scholar 11 Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G, McKiernan G, Christensen I, Oster M, Henigsmann H, Wilford H, Kokoschka E, Rehle T, Perez M, Stingl G, Laroche L. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297-303. 10.1056/NEJM198702053160603 CASPubMedWeb of Science®Google Scholar 12 Vamvakas EC, Pineda AA. Selective extraction of plasma constituents. In: BC McLeod, TH Price, R Weinstein, editors. Apheresis: principles and practice. 2nd ed. Bethesda (MD): AABB Press; 2003. p. 437-76. Google Scholar 13 Abel JJ, Rowntree LG, Turner BB. Plasma removal with return of corpuscles (plasmapheresis). J Pharmacol Exp Ther 1914; 5: 625-41. CASGoogle Scholar 14 Schwab PJ, Fahey JL. Treatment of Waldenström's macroglobulinemia by plasmapheresis. N Engl J Med 1960; 263: 574-9. 10.1056/NEJM196009222631202 CASPubMedWeb of Science®Google Scholar 15 Vallejos CS, McCredie KB, Brittin GM, Freireich EJ. Biological effects of repeated leukapheresis of patients with chronic myelogenous leukemia. Blood 1973; 42: 925-33. CASPubMedWeb of Science®Google Scholar 16 Greenberg B, Watson-Williams E. Successful control of life-threatening thrombocytosis with a blood processor. Transfusion 1975; 15: 620-2. 10.1046/j.1537-2995.1975.15676082242.x CASPubMedWeb of Science®Google Scholar 17 Watson WJ, Katz VL, Bowes WA. Plasmapheresis during pregnancy. Obstet Gynecol 1990; 76: 451-7. PubMedWeb of Science®Google Scholar 18 Jones JV, Cumming RH, Bucknall RC, Asplin CM. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976; 1: 709-11. 10.1016/S0140-6736(76)93088-9 PubMedWeb of Science®Google Scholar 19 Klein HG, Balow JE, Dau PC, Hamburger MI, Leitman SF, Pineda AA, Tindall RS. Clinical applications of therapeutic apheresis. J Clin Apheresis 1986; 3: 1-92. 10.1002/jca.2920030104 Web of Science®Google Scholar 20 Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, McLeod BC. An overview of current management. J Clin Apher 1993; 189-94. 10.1002/jca.2920080402 CASPubMedGoogle Scholar 21 McLeod BC. Introduction to the third special issue: Clinical applications of therapeutic apheresis. J Clin Apher 2000; 15: 1-5. 10.1002/(SICI)1098-1101(2000)15:1/2 3.0.CO;2-R CASPubMedWeb of Science®Google Scholar 22 Smith JW, Weinstein R, Lankford K. Therapeutic apheresis—a summary of current indication categories endorsed by AABB and ASFA. Transfusion 2003; 43: 820-2. 10.1046/j.1537-2995.2003.00397.x PubMedWeb of Science®Google Scholar 23 Szczepiorkowski ZW, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Shaz BH, Weinstein R, Wirk A, Winters JL. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22: 106-75. 10.1002/jca.20129 PubMedWeb of Science®Google Scholar 24 McLeod BC. An approach to evidence based therapeutic apheresis. J Clin Apher 2002; 17: 124-32. 10.1002/jca.10029 PubMedWeb of Science®Google Scholar 25 Reeves JH, Butt WW, Shann F, Layton JE, Stewart A, Waring PM, Presneill JJ. Continuous plasmafiltration in sepsis syndrome. Crit Care Med 1999; 27: 2096-104. 10.1097/00003246-199910000-00003 CASPubMedWeb of Science®Google Scholar 26 Nakae H, Asanuma Y, Tajimi K. Cytokine removal by plasma exchange with continuous hemofiltration in critically ill patients. Therap Apher 2002; 6: 419-24. 10.1046/j.1526-0968.2002.00464.x CASPubMedWeb of Science®Google Scholar 27 Shariatmader S, Nassiri M, Vincek V. Effect of plasma exchange on cytokines measured by multianalyte beads in thrombotic thrombocytopenic purpura. Am J Hematol 2005; 79: 83-8. 10.1002/ajh.20342 CASPubMedWeb of Science®Google Scholar 28 Jones JV, Cumming RH, Bacon PA, Evers J, Fraser ID, Bothamley J, Tribe CR, Davis P, Hughes GR. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus. Q J Med 1979; 48: 555-76. CASPubMedWeb of Science®Google Scholar 29 Kater L, Derksen RH, Houwert DA, Hené RJ, Struyvenberg A, Gmelig Meyling FH, Verroust P. Effect of plasmapheresis in active systemic lupus erythematosus. Neth J Med 1981; 24: 209-16. CASPubMedWeb of Science®Google Scholar 30 Parry HF, Moran CJ, Snaith ML, Richards JD, Goldstone AH, Nineham LJ, Hay FC, Morrow WJ, Roitt IM. Plasma exchange in systemic lupus erythematosus. Ann Rheum Dis 1981; 40: 224-8. 10.1136/ard.40.3.224 CASPubMedWeb of Science®Google Scholar 31 Jones JV. Plasmapheresis in systemic lupus erythematosus. Clin Rheum Dis 1982; 8: 243-60. CASPubMedWeb of Science®Google Scholar 32 Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326: 1373-9. 10.1056/NEJM199205213262101 CASPubMedWeb of Science®Google Scholar 33 Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, Euler HH. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher 1998; 13: 163-6. 10.1002/(SICI)1098-1101(1998)13:4 3.0.CO;2-1 CASPubMedWeb of Science®Google Scholar 34 Schroeder JO, Schwab U, Zeuner R, Fastenrath S, Euler HH. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus: preliminary results of the LPSG trial. Arthritis Rheum 1997; 40: 325. Google Scholar 35 Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104. 10.1212/WNL.35.8.1096 PubMedWeb of Science®Google Scholar 36 French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-61. 10.1002/ana.410220612 PubMedWeb of Science®Google Scholar 37 French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992; 32: 94-7. 10.1002/ana.410320115 CASPubMedWeb of Science®Google Scholar 38 Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984; 63: 162-9. 10.1182/blood.V63.1.162.162 CASPubMedWeb of Science®Google Scholar 39 Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126: 896-9. 10.1016/S0022-3476(95)70204-0 CASPubMedWeb of Science®Google Scholar 40 Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5-11. 10.1056/NEJM199807023390102 CASPubMedWeb of Science®Google Scholar 41 Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353: 2769-78. 10.1056/NEJMoa050460 CASPubMedWeb of Science®Google Scholar 42 Pineda AA. Introduction. In: AA Pineda, editor. Selective plasma component removal. Mount Kisco (NY): Futura; 1984. p. vii-x. Google Scholar 43 Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. Trans Am Ophthalmol Soc 2006; 104: 221-31. PubMedGoogle Scholar 44 Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dall'Amico R, Dorent R, Rogers JG, Radovancević B, Taylor DO, Jeevanandam V, Marboe CC. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998; 339: 1744-51. 10.1056/NEJM199812103392404 CASPubMedWeb of Science®Google Scholar 45 Flowers ME, Apperley JF, Van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008; 112: 2667-74. 10.1182/blood-2008-03-141481 CASPubMedWeb of Science®Google Scholar 46 Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S, Adacolumn Study Group. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008; 135: 400-9. 10.1053/j.gastro.2008.04.023 CASPubMedWeb of Science®Google Scholar 47 Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN, Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure. Ann Intern Med 2005; 143: 777-84. 10.7326/0003-4819-143-11-200512060-00005 PubMedWeb of Science®Google Scholar 48 Cserti C, Haspel R, Stowell C, Dzik W. Light chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007; 47: 511-4. 10.1111/j.1537-2995.2006.01143.x CASPubMedWeb of Science®Google Scholar 49 Cardella CJ, Sutton D, Uldall PR, De Veber GA. Intensive plasma exchange and renal transplant rejection. Lancet 1977; 1: 264. 10.1016/S0140-6736(77)91069-8 CASPubMedWeb of Science®Google Scholar 50 Rifle G, Chalopin JM, Ture JM, Guigner F, Vialtel P, Dechelette E, Chenais E, Cordonsier D. Plasmapheresis in the treatment of renal allograft rejections. Transplant Proc 1979; 11: 20-6. CASPubMedWeb of Science®Google Scholar 51 Adams MB, Kauffman HM Jr, Hussey CV, Gottschall JL, Hackbarth SA, Buchmann EV. Plasmapheresis in the treatment of refractory renal allograft rejection. Transplant Proc 1981; 13: 491-4. PubMedWeb of Science®Google Scholar 52 Vangelista A, Frascà GM, Nanni Costa A, Stefoni S, Bonomini V. Value of plasma exchange in renal transplant rejection induced by specific HLA antibodies. Trans Am Soc Artif Intern Organs 1982; 28: 599-603. CASPubMedWeb of Science®Google Scholar 53 Cardella CJ, Sutton DM, Falk JA, Katz A, Uldall PR, DeVeber GA. Effect of intense plasma exchange on renal transplant rejection and serum cytotoxic antibody. Transplant Proc 1978; 10: 617-9. CASPubMedWeb of Science®Google Scholar 54 Bankowski LH, Corteste J, Lutton JL, Saunders PH. Plasmapheresis—adjunctive treatment for steroid-resistant rejection in renal transplantation. J Urol 1984; 131: 14. 10.1016/S0022-5347(17)50170-6 PubMedWeb of Science®Google Scholar 55 Soulillou JP, Guyot C, Guimbretiere J, Girard M, Ythier A, Bignon JD, Hourmant M, Guenel J. Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. Nephron 1983; 35: 158-62. 10.1159/000183067 CASPubMedWeb of Science®Google Scholar 56 Allen NH, Ayer P, Geoghegan T, Harris K, Lee HA, Slapak M. Plasma exchange in acute renal allograft rejection: a controlled trial. Transplantation 1983; 35: 425-8. 10.1097/00007890-198305000-00006 CASPubMedWeb of Science®Google Scholar 57 Kirubakaran MG, Disney AP, Norman J, Pugsley DJ, Mathew TH. A controlled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 1981; 32: 164-5. 10.1097/00007890-198108000-00019 PubMedWeb of Science®Google Scholar 58 Bonomini V, Vangelista A, Frascà GM, Di Felice A, Liviano D'Arcangelo G. Effects of plasmapheresis in renal transplant rejection: a controlled study. Trans Am Soc Artif Intern Organs 1985; 31: 698-703. PubMedGoogle Scholar 59 Blake P, Sutton D, Cardella C. Plasma exchange in acute renal transplant rejection. Prog Clin Biol Res 1990; 337: 249-52. CASPubMedGoogle Scholar 60 Crespo M, Pascual M, Tolkoff-Rubin N, Mauiyyedi S, Collins AB, Fitzpatrick D, Farrell ML, Williams WW, Delmonico FL, Cosimi AB, Colvin RB, Saidman SL. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-8. 10.1097/00007890-200103150-00013 CASPubMedWeb of Science®Google Scholar 61 Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-95. 10.1097/00007890-200009270-00006 CASPubMedWeb of Science®Google Scholar 62 White NB, Greenstein SM, Cantafio AW, Schechner R, Glickligh D, McDonough P, Pullman J, Mohandas K, Boctor F, Uehlinger J, Tellis V. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004; 78: 772-4. 10.1097/01.TP.0000128194.55934.48 CASPubMedWeb of Science®Google Scholar 63 Sonnenday CJ, Ratner LE, Zachary AA, Burdick JF, Samaniego MD, Kraus E, Warren DS, Montgomery RA. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34: 1614-6. 10.1016/S0041-1345(02)03044-0 CASPubMedWeb of Science®Google Scholar 64 Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr. Transplantation 2004; 8: 535-42. 10.1111/j.1399-3046.2004.00214.x PubMedWeb of Science®Google Scholar 65 Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 2008; 86: 96-103. 10.1097/TP.0b013e318176ae2c PubMedWeb of Science®Google Scholar 66 Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 2009; 87: 268-73. 10.1097/TP.0b013e3181919a16 PubMedWeb of Science®Google Scholar 67 Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion 2008; 48: 2453-60. 10.1111/j.1537-2995.2008.01857.x PubMedWeb of Science®Google Scholar 68 Haas M, Montgomery RA, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, Simpkins CE, Warren DS, Lepley D, Zachary AA, Kraus ES. Subclinical acute anti-body mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576-85. 10.1111/j.1600-6143.2006.01657.x CASPubMedWeb of Science®Google Scholar 69 Pollinger HS, Stegall MD, Gloor JM, Moore SB, Degoey SR, Ploeger NA, Park WD. Kidney transplantation in patients with antibodies against donor HLA Class II. Am J Transplant 2007; 7: 857-63. 10.1111/j.1600-6143.2006.01699.x CASPubMedWeb of Science®Google Scholar 70 Lazda VA. Identification of patients at risk for inferior renal allograft outcome by a strongly positive B cell flow cytometry crossmatch. Transplantation 1994; 57: 964-9. 10.1097/00007890-199403270-00033 CASPubMedWeb of Science®Google Scholar 71 Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-300. 10.1056/NEJMoa067160 CASPubMedWeb of Science®Google Scholar 72 Carter V, Shenton BK, Jaques B, Turner D, Talbot D, Gupta A, Chapman CE, Matthews CJ, Cavanagh G. Vimentin antibodies: A non-HLA antibody as a potential risk factor in renal transplantation. Transplant Proc 2005; 37: 654-7. 10.1016/j.transproceed.2004.12.043 CASPubMedWeb of Science®Google Scholar 73 Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer H, Luft FC, Wallukat G. Angiotensin II type-1 receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-69. 10.1056/NEJMoa035717 CASPubMedWeb of Science®Google Scholar 74 Sumitran-Holgersson S. Relevance of MICA and other non-HLA antibodies in clinical transplantation. Cur Opin Immunol 2008; 20: 607-13. 10.1016/j.coi.2008.07.005 CASPubMedWeb of Science®Google Scholar 75 Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31. 10.1016/S0140-6736(02)08220-X PubMedWeb of Science®Google Scholar 76 Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994; 44: 16-20. 10.1212/WNL.44.1.16 CASPubMedWeb of Science®Google Scholar 77 Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, Van Den Noort S, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78. 10.1212/WNL.58.2.169 CASPubMedWeb of Science®Google Scholar 78 Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255: 1449-63. 10.1007/s00415-008-0061-1 CASPubMedWeb of Science®Google Scholar 79 Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Opin Neurol 2007; 20: 255-60. 10.1097/WCO.0b013e32814f1c6b PubMedWeb of Science®Google Scholar 80 Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-15. 10.1016/S1474-4422(07)70216-8 CASPubMedWeb of Science®Google Scholar 81 Galetta SL, Bennett J. Neuromyelitis optica is a variant of multiple sclerosis. Arch Neurol 2007; 64: 901-3. 10.1001/archneur.64.6.901 PubMedWeb of Science®Google Scholar 82 Dau PC, Petajan JH, Johnson KP, Panitch HS, Bornstein MB. Plasmapheresis in multiple sclerosis: preliminary findings. Neurology 1980; 30: 1023-8. 10.1212/WNL.30.10.1023 CASPubMedWeb of Science®Google Scholar 83 Weiner HL, Dawson DM. Plasmapheresis in multiple sclerosis: preliminary study. Neurology 1980; 30: 1029-33. 10.1212/WNL.30.10.1029 CASPubMedWeb of Science®Google Scholar 84 Khatri BO, McQuillen MP, Hoffmann RG, Harrington GJ, Schmoll D. Plasma exchange in chronic progressive multiple sclerosis: a long term study. Neurology 1991; 41: 409-14. 10.1212/WNL.41.3.409 PubMedWeb of Science®Google Scholar 85 Tindall RS, Walker JE, Ehle AL, Near L, Rollins J, Becker D. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone. Neurology 1982; 32: 739-43. 10.1212/WNL.32.7.739 CASPubMedWeb of Science®Google Scholar 86 Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL. Intensive immunosuppression in progressive multiple sclerosis: a randomized three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-80. 10.1056/NEJM198301273080401 CASPubMedWeb of Science®Google Scholar 87 Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985; 35: 312-9. 10.1212/WNL.35.3.312 CASPubMedWeb of Science®Google Scholar 88 Weiner HL, Dau PC, Khatri BO, Petajan JH, Birnbaum G, McQuillen MP, Fosburg MT, Feldstein M, Orav EJ. Double-blind study of true versus sham plasma exchange in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39: 1143-9. 10.1212/WNL.39.9.1143 PubMedWeb of Science®Google Scholar 89 Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6. PubMedGoogle Scholar 90 Noseworthy JH, Vandervoort MK, Penman M, Ebers G, Shumak K, Seland TP, Roberts R, Yetisir E, Gent M, Taylor DW. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991; 337: 1540-1. 10.1016/0140-6736(91)93226-Y CASPubMedWeb of Science®Google Scholar 91 Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-86. 10.1002/1531-8249(199912)46:6 3.0.CO;2-Q CASPubMedWeb of Science®Google Scholar 92 Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139-59. 10.1097/00005792-196603000-00003 Web of Science®Google Scholar 93 Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977; 50: 413-7. 10.1182/blood.V50.3.413.413 CASPubMedWeb of Science®Google Scholar 94 Okuno T, Kosova L. Plasmapheresis for thrombotic thrombocytopenic purpura. Transfusion 1979; 19: 342-4. 10.1046/j.1537-2995.1979.19379204221.x CASPubMedWeb of Science®Google Scholar 95 Taft EG. Thrombotic thrombocytopenic purpura and the dose of plasma exchange. Blood 1979; 54: 842-9. PubMedWeb of Science®Google Scholar 96 Myers TJ, Wakem CJ, Ball ED, Tremont SJ. Thrombotic thrombocytopenic purpura: combined treatment with plasmapheresis and antiplatelet agents. Ann Intern Med 1980; 92: 149-55. 10.7326/0003-4819-92-2-149 CASPubMedWeb of Science®Google Scholar 97 McLeod B, Wu K, Knospe W. Plasmapheresis in thrombotic thrombocytopenic purpura. Arch Intern Med 1980; 140: 1059-60. CASPubMedWeb of Science®Google Scholar 98 Breckenridge RL Jr, Solberg LA, Pineda AA, Petitt RM, Dharkar DD. Treatment of thrombotic thrombocytopenic purpura with plasma exchange, antiplatelet agents, corticosteroid, and plasma infusion: Mayo Clinic experience. J Clin Apher 1982; 1: 6-13. 10.1002/jca.2920010104 PubMedGoogle Scholar 99 Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977; 297: 1386-9. 10.1056/NEJM197712222972507 CASPubMedWeb of Science®Google Scholar 100 George JN. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-35. 10.1056/NEJMcp053024 CASPubMedWeb of Science®Google Scholar 101 Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32: 292-308. 10.1038/ki.1987.206 PubMedWeb of Science®Google Scholar 102 Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-8. 10.1182/blood-2008-02-078170 CASPubMedWeb of Science®Google Scholar 103 Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome; clinical experience in 108 patients. N Engl J Med 1991; 325: 398-403. 10.1056/NEJM199108083250605 PubMedWeb of Science®Google Scholar 104 Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1997; 325: 393-7. 10.1056/NEJM199108083250604 PubMedWeb of Science®Google Scholar 105 Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84. 10.1056/NEJM199811263392202 CASPubMedWeb of Science®Google Scholar 106 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94. 10.1056/NEJM199811263392203 CASPubMedWeb of Science®Google Scholar 107 Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Camitta B, Lawton C, Garbrecht F, Gottschall JL. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 271-5. PubMedWeb of Science®Google Scholar 108 Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-9. 10.1182/blood-2003-11-4035 CASPubMedWeb of Science®Google Scholar 109 Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-72. 10.1182/blood.V98.6.1765 CASPubMedWeb of Science®Google Scholar 110 Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS-13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-8. 10.1182/blood-2003-01-0193 CASPubMedWeb of Science®Google Scholar 111 Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004; 44: 146-50. 10.1111/j.1537-2995.2004.00626.x CASPubMedWeb of Science®Google Scholar 112 Zakarija A, Bandarenko N, Kwaan H, Pandey D, Cursio J, Tevar A, Buffie C, Weiss I, Ortel T, Winters J, Bennett CL. Risk factors for thrombotic thrombocytopenic purpura: results of the surveillance, epidemiology, and risk factors for TTP (SERF-TTP) group. J Clin Apher 2007; 22: 51-2. (abstract). PubMedGoogle Scholar 113 Studt JD, Böhm M, Budde U, Girma JP, Varadi K, Lämmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 1: 1882-7. 10.1046/j.1538-7836.2003.00385.x CASPubMedWeb of Science®Google Scholar 114 Tripodi A, Chantarangkul V, Böhm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-9. 10.1111/j.1538-7836.2004.00879.x CASPubMedWeb of Science®Google Scholar 115 Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, López JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-9. 10.1182/blood-2002-05-1401 CASPubMedWeb of Science®Google Scholar 116 Dong JF, Moake JL, Bernardo A, Fujikawa K, Ball C, Nolasco L, López JA, Cruz MA. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003; 278: 29633-9. 10.1074/jbc.M301385200 CASPubMedWeb of Science®Google Scholar 117 Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-6. 10.1111/j.1538-7836.2005.01360.x CASPubMedWeb of Science®Google Scholar Citing Literature Volume50, Issue7July 2010Pages 1413-1426 ReferencesRelatedInformation
Referência(s)